All In Biotech

Drug Trial Radar · NCT04961567

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 562 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

562

Actual

Start

Jul 16, 2021

Primary completion

Sep 27, 2026

Study completion Mar 16, 2027

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jul 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: \- How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), the British Isles Lupus Activity Group-2004 index (BILAG-2004), and the BILAG-BASED Combined Lupus Assessment (BICLA), among others. Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • LitifilimabDrug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52Time frame: Week 52

Locations

177 sites in 17 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Glendale, Arizona

  • Care Access Research - Huntington BeachCare Access Research - Huntington Beach

    Huntington Beach, California

  • Valerius Medical Group

    Los Alamitos, California

  • The Practice of Medicine

    Los Angeles, California

  • R. Srinivasan, M.D., Inc. dba Monterey Park Medical Center

    Monterey Park, California

  • Neurovations

    Napa, California

  • Joo-Hyung Lee MD

    Orange, California

  • Medvin Clinical Research

    Whittier, California

  • RASF - Clinical Research Center

    Boca Raton, Florida

  • University of Florida

    Gainesville, Florida

  • Vida Clinical Research

    Kissimmee, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • HMD Research, LLC

    Orlando, Florida

  • Clinical Research of West Florida, Inc.

    Tampa, Florida

  • The Emory Clinic Emory University

    Atlanta, Georgia

  • Jefrey Lieberman, M.D., P.C.

    Decatur, Georgia

  • Southeastern Rheumatology Alliance dba Arthritis Center of North Georgia

    Gainesville, Georgia

  • RNA America Health Sciences

    Gainesville, Georgia

  • EBGS Clinical Trials

    Snellville, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Boston University School of Medicine

    Boston, Massachusetts

  • DM Clinical Research - Boston

    Brookline, Massachusetts

  • University of Massachusetts

    Worcester, Massachusetts

  • Saint Louis Rheumatology

    St Louis, Missouri

  • Arthritis & Osteoporosis Associates, PA

    Freehold, New Jersey

  • Arthritis and Osteoporosis Associates of New Mexico

    Las Cruces, New Mexico

  • DJL Clinical Research, PLLC

    Charlotte, North Carolina

  • Carolina Arthritis Associates

    Wilmington, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • STAT Research

    Dayton, Ohio

  • Piedmont Arthritis Clinic, P.A.

    Greenville, South Carolina

  • Low Country Rheumatology, PA

    Summerville, South Carolina

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Arthritis & Rheumatology Institute

    Allen, Texas

  • Office of John P. Lavery M.D., PA

    Allen, Texas

  • Tekton Research

    Austin, Texas

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas

  • R and H Clinical Research

    Katy, Texas

  • Prime Clinical Research

    Mansfield, Texas

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.